ORLANDO — In this exclusive video from Advances in IBD 2017, Feza Remzi, MD, director of the IBD Center at NYU Langone Health, and professor of surgery at NYU School of Medicine, discusses new research published in JAMA that showed patients with inflammatory bowel disease who took anti-TNF agents and thiopurines showed an increased risk for lymphoma.
You can read more about that study here.
“This was a very important study from our colleagues from France, and what they found [was] specifically, the multi-modality therapy combining thiopurines and biologics has at least a 6-times higher rate [of lymphoma] compared to non-users,” he told Healio Gastroenterology and Liver Disease. “To me this is very concerning ... biologics and thiopurines are a very important and critical part of the therapy for our patients with IBD. At the same time, this is important information our patients need to know. There are different options available for the therapy of our patients, such as surgery, [which] can be a great option.”
Disclosures: Remzi reports no relevant financial disclosures.